抗苗勒管激素可减轻环磷酰胺所致损伤及PI3K信号激活,而雷帕霉素仅减轻PI3K信号激活:人卵巢皮质体外研究
该体外研究将17名健康女性(21-41岁)剖宫产时的卵巢皮质活检组织培养24小时,分别暴露于环磷酰胺活性代谢物4-氢过氧环磷酰胺(4-HC)单独、4-HC+雷帕霉素或4-HC+抗苗勒管激素(AMH)。结果显示4-HC增加不健康原始和过渡卵泡比例并上调PI3K信号;AMH可显著减少约一半的卵泡损伤并减轻PI3K激活,雷帕霉素仅减轻PI3K信号激活而对卵泡健康无保护作用。
要点
- 4-HC暴露增加不健康原始和过渡卵泡比例(P<0.0001和P<0.01)并激活PI3K信号。
- AMH使两种剂量4-HC导致的卵泡损伤显著减少约一半(P<0.0001)。
- 雷帕霉素对卵泡健康无保护作用,仅减轻低剂量4-HC下的PI3K信号激活。
核心结论
- 环磷酰胺暴露损害人卵巢皮质原始和过渡卵泡健康并上调PI3K信号,AMH可减轻这两种化疗诱导效应,而雷帕霉素仅减轻PI3K信号上调。
研究设计与样本
- 体外研究:取17名健康女性(21-41岁,平均31.8±4.9岁)择期剖宫产时的新鲜卵巢皮质活检组织,切成小碎片培养24小时。
- 分别暴露于溶剂对照(DMSO)、4-HC单独、4-HC+雷帕霉素或4-HC+AMH;4-HC设0.2 μM和2 μM两个剂量,分别使用7名(27-41岁)和6名(21-34岁)女性的活检组织。
- 另用4名女性(28-38岁)的活检组织研究雷帕霉素或AMH单独效应;通过组织学分析卵泡分期和健康,Western blotting和免疫染色评估PI3K信号激活(AKT磷酸化和磷酸化FOXO3A染色强度)。
主要发现
- 与溶剂对照相比,两种剂量4-HC均增加不健康原始卵泡比例(P<0.0001)和过渡卵泡比例(低剂量P<0.01,高剂量P<0.01)。
- AMH使两种剂量4-HC下的卵泡损伤显著减少约一半(P<0.0001),雷帕霉素对卵泡健康无保护作用。
- AMH或雷帕霉素单独培养对卵泡健康无影响。
- 4-HC暴露激活PI3K信号:Western blotting显示AKT磷酸化增加,免疫染色显示非生长卵母细胞磷酸化FOXO3A染色增加。
- 雷帕霉素在低剂量4-HC实验中减轻PI3K信号激活;AMH在两种剂量下均减轻PI3K激活(AKT磷酸化和磷酸化FOXO3A染色强度均降低)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 这些体外研究可能无法复制体内暴露情况。
- 需要更长的实验持续时间来确定观察到的效应是否转化为不可修复的卵巢卵泡缺陷。
- 未来工作需要考量化疗治疗和潜在保护剂的持续效应,以确保这些药物不损害卵母细胞的发育能力或导致携带累积DNA损伤的卵母细胞存活,这可能对潜在后代产生不良后果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What are the effects of cyclophosphamide exposure on the human ovary and can anti-Mullerian hormone (AMH) and rapamycin protect against these? SUMMARY ANSWER: Exposure to cyclophosphamide compromises the health of primordial and transitional follicles in the human ovarian cortex and upregulates PI3K signalling, indicating both direct damage and increased follicular activation; AMH attenuates both of these chemotherapy-induced effects, while rapamycin attenuates only PI3K signalling upregulation. WHAT IS KNOWN ALREADY: Studies primarily in rodents demonstrate that cyclophosphamide causes direct damage to primordial follicles or that the primordial follicle pool is depleted primarily through excessive initiation of follicle growth. This increased follicular activation is mediated via upregulated PI3K signalling and/or reduced local levels of AMH production due to lost growing follicles. Furthermore, while rodent data show promise regarding the potential benefits of inhibitors/protectants alongside chemotherapy treatment to preserve female fertility, there is no information about the potential for this in humans. STUDY DESIGN, SIZE, DURATION: Fresh ovarian cortical biopsies were obtained from 17 healthy women aged 21-41 years (mean ± SD: 31.8 ± 4.9 years) at elective caesarean section. Biopsies were cut into small fragments and cultured for 24 h with either vehicle alone (DMSO), the active cyclophosphamide metabolite 4-hydroperoxycyclophosphamide (4-HC) alone, 4-HC + rapamycin or 4-HC+AMH. Two doses of 4-HC were investigated, 0.2 and 2 μM in separate experiments, using biopsies from seven women (aged 27-41) and six women (aged 21-34), respectively. Biopsies from four women (aged 28-38) were used to investigate the effect of rapamycin or AMH only. PARTICIPANTS/MATERIALS, SETTING, METHODS: Histological analysis of ovarian tissue was undertaken for follicle staging and health assessment. Western blotting and immunostaining were used to assess activation of PI3K signalling by measuring phosphorylation of AKT and phosphorylated FOXO3A staining intensity, respectively. MAIN RESULTS AND THE ROLE OF CHANCE: Exposure to either dose of 4-HC caused an increase in the proportion of unhealthy primordial (P < 0.0001, both doses) and transitional follicles (P < 0.01 for low dose and P < 0.01 for high dose) compared to vehicle. AMH significantly reduced follicle damage by approximately half in both of the investigated doses of 4-HC (P < 0.0001), while rapamycin had no protective effect on the health of the follicles. Culture with AMH or rapamycin alone had no effect on follicle health. Activation of PI3K signalling following 4-HC exposure was demonstrated by both Western blotting data showing that 4-HC increased in AKT phosphorylation and immunostaining showing increased phosphorylated FOXO3A staining of non-growing oocytes. Treatment with rapamycin reduced the activation of PI3K signalling in experiments with low doses of 4-HC while culture with AMH reduced PI3K activation (both AKT phosphorylation and phosphorylated FOXO3A staining intensity) across both doses investigated. LIMITATIONS, REASONS FOR CAUTION: These in vitro studies may not replicate in vivo exposures. Furthermore, longer experiment durations are needed to determine whether the effects observed translate into irreparable deficits of ovarian follicles. WIDER IMPLICATIONS OF THE FINDINGS: These data provide a solid foundation on which to explore the efficacy of AMH in protecting non-growing ovarian follicles from gonadotoxic chemotherapies. Future work will require consideration of the sustained effects of chemotherapy treatment and potential protectants to ensure these agents do not impair the developmental competence of oocytes or lead to the survival of oocytes with accumulated DNA damage, which could have adverse consequences for potential offspring. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by grants from TENOVUS Scotland, the Academy of Medical Sciences (to R.R.), the Medical Research Council (G1100357 to R.A.A., MR/N022556/1 to the MRC Centre for Reproductive Health), and Merck Serono UK (to R.A.A.). R.R., H.L.S., N.S., and E.E.T. declare no conflicts of interest. R.A.A. reports grants and personal fees from Roche Diagnostics and Ferring Pharmaceuticals, and personal fees from IBSA and Merck outside the submitted work. TRIAL REGISTRATION NUMBER: N/A.
引用
- Rosario R, Stewart HL, Spears N, et al. Anti-Mullerian hormone attenuates both cyclophosphamide-induced damage and PI3K signalling activation, while rapamycin attenuates only PI3K signalling activation, in human ovarian cortex in vitro. Hum Reprod. 2024. PMID: 38070496. doi:10.1093/humrep/dead255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。